# SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT

> **NCT04387695** · PHASE3 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 54 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma
- Portal Vein Thrombosis

## Interventions

- **RADIATION:** SBRT+TACE+Sorafenib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT04387695
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-30
- **Primary completion:** 2023-08-01
- **Final completion:** 2023-08-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04387695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04387695, "SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT04387695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*